BOSTON SCIENTIFIC CORP
In the published model solve dated 2026-Q2, anchored at $46.85, BOSTON SCIENTIFIC CORP (BSX) is priced for +4.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed August 7, 2026 from SEC EDGAR filings.
• The Cardiovascular business, roughly twice the size of MedSurg at $13.3 billion of revenue, grew net sales 8.3% in the June 2026 quarter while MedSurg grew 5.9%, and the whole company grew 7.5% to $5.442 billion [Source: Q2 2026 earnings release, July 29, 2026]. • Guidance points sharply lower from here: third-quarter net sales growth is guided to roughly 3 to 5 percent, against 7.0 percent organic growth just delivered, and on July 21, 2026 the board approved a restructuring plan carrying pre
Is BSX overvalued? See what's priced in →
1,617 institutional managers reported holding BSX in 13F filings for the quarter ended 2026-03-31. Together they hold about 87% of the company; the top 10 hold 39%. 160 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 29.8M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (1.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BSX's share count grew 4.5% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BSX over the trailing three years: 2024: 1 buy totaling $5k; 2026: 3 buys totaling $554k. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BSX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -1.4% | +2.8% |
| 2023-11-02 | -0.9% | +10.8% |
| 2024-02-21 | +5.5% | +10.9% |
| 2024-05-02 | +6.2% | +5.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BSX's latest 8-K filings: 2026-08-26 (items 8.01); 2026-07-29 (items 2.02, 9.01); 2026-07-27 (items 2.05); 2026-05-18 (items 8.01, 9.01); 2026-05-18 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 7, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.